Infectious Disease Therapeutics Market

Infectious Disease Therapeutics Market Size (2022 to 2027)

The global infectious disease therapeutics market is predicted to grow at a CAGR of 7.96% from 2022 to 2027. The market is forecasted to grow to USD 166.46 billion by 2027 from USD 113.5 billion in 2022.

Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, and parasites. These diseases can be transmitted from one another by direct contact or indirect contact, and Anti-infective drugs are used to inhibit the disease's growth. These drugs can act through the host defense system and directly target the causative agent. Globally, significant problems to public health are posed by infectious diseases such as malaria, HIV, tuberculosis, influenza, hepatitis A, and hepatitis C. In addition, these diseases are the primary cause of death in the world.

MARKET DRIVERS:

Factors such as Y-O-Y rise in the incidence of infectious diseases, the growing use of direct-acting antiviral, increasing healthcare expenditure, the growing geriatric population, rising healthcare awareness, and increasing government funding in developing countries are primarily propelling the growth of the global infectious disease therapeutics market.

The growing prevalence of the acceptance of advanced technological developments in healthcare centers is ascribed to bolstering the market's demand. Furthermore, increasing disposable income in developed and developing countries also outshines the growth rate of this market. Moreover, raising awareness of various diseases and knowing the benefits of early diagnosis among individuals is lucrative to surge growth opportunities for the infectious disease therapeutics market. Also, the introduction of reimbursement schemes in favor of ordinary people is lavishing this market's demand.

MARKET RESTRAINTS:

However, the lack of skilled persons in manufacturing effective drugs hinders the market's growth. Rapid changes in economic strategies may also negatively impact the development of the infectious therapeutics market. The availability of alternative methods at a lower cost and less knowledge of generic erosion are significant challenges to the market participants. On the other hand, the primary factor restraining the market's growth is generic erosion and patent expiration of infectious disease drugs.

Impact of COVID-19 on the global infectious disease therapeutics market:

The outbreak of COVID-19 is unexpectedly affecting many countries. The virus affects vast numbers of people, especially patients with infectious diseases. The rising cases of COVID-19 everywhere escalate the growth rate of the infectious disease therapeutics market. Many key players are racing to find a vaccine or drugs for the novel coronavirus. Meanwhile, infectious disease therapeutics are the only way to control the spread of infectious diseases. Therefore, the market's growth is expected to accelerate slowly during the forecast period. 

REPORT COVERAGE:

This research report on the global infectious disease therapeutics market has been segmented and sub-segmented based on the mode of treatment, target organism, infection type, distribution channels & region.

Infectious Disease Therapeutics Market - By Mode of Treatment:

• Drugs     
• Vaccines    

Based on the mode of treatment, the drug mode of treatment is predicted to register the largest share of the global market during the forecast period. The rising elderly population worldwide and an increase in spending on healthcare, especially in well-developed countries, are promoting the market’s growth rate.

Infectious Disease Therapeutics Market - By Target Organism:

• Antibacterial      
• AntifuAntiviralviral  
• Antiparasite      
• others     

Based on the target organism, the antibacterial segment accounted for a significant share of the global market in 2021 and is estimated to continue its dominance during the forecast period. A rise in the number of people suffering from various infectious diseases like HIV, tuberculosis, influenza, hepatitis A, and hepatitis C increases market demand. In addition, growing disposable income in urban areas is further favoring the market’s growth rate.     

Infectious Disease Therapeutics Market – By Infection type: 

• Bacterial  
• Viral      
• Fungal    
• Parasitic  
• Others    

Based on infection type, the bacterial infection segment has been growing faster over the past few years and is also anticipated to reach the highest CAGR. Introducing innovative products manufactured with advanced technology boosts the market's growth rate.

Infectious Disease Therapeutics Market – By Distribution Channels: 

• Hospitals  
• Clinics     
• Others    

Based on distribution channels, the hospital segment is forecasted to lead among all during the forecast period. A rise in hospitals' construction with the latest equipment is fuelling the growth rate of the infectious disease therapeutics market.

Infectious Disease Therapeutics Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

The North American infectious disease therapeutics market is expected to account for the highest share in the global market, followed by Asia-Pacific and Europe, owing to the rising incidence of infectious diseases and the increasing aging population. However, Asia-Pacific is projected to account for the highest CAGR over the forecast period due to increasing government funding in emerging countries such as India and China. North America dominated the infectious disease therapeutics market with the highest share of 38.6% worldwide. The market in this region is accredited because of the regular increase of infectious diseases, growing outgoings for healthcare, and mounting alertness in healthcare. In addition, escalating funds and investments from the government, especially in developed nations of the region, boosts market growth. The United States is leading the market due to manufacturers and many clinical trials developing novel drugs to treat infectious diseases. Canada is observed to have rapid growth in the region.

The Europe infectious disease therapeutics market was the second-largest regional market worldwide in 2021, and the growth of this regional market is majorly driven by the increased inpatient count, the vast amount spent on healthcare, and support from the European government towards research and development activities for the drug development used for treating infectious diseases in patients. Nearly 32,000 predicted mortalities with tuberculosis and approximately 323,000 new tuberculosis cases were recorded in Europe in 2015, as per the World Health Organization (WHO). In February 2018, more than 44,000 people died from lung diseases associated with seasonal influenza in Europe. 

The infectious disease therapeutics market in the Asia-Pacific is believed to have the quickest growth. Increasing patient population, acceptable government policies such as a decrease in excise and customs duty, and later exceptions in service tax, particularly in India, are accelerating the region's market growth. Rapid ongoing enhancements in countries like India and China. For instance, the Indian Institute of Science researchers have invented a novel drug combination to treat tuberculosis better. 

The infectious disease therapeutics market in Latin America is predicted to have constant and fixed growth. The market in this region is driven because of the escalating older people population and increasing healthcare cognizance. Brazil is dominating the market in the area.

The infectious disease therapeutics market in Middle East & Africa held a minimal share of the global market in 2021 and is estimated to register a healthy CAGR during the forecast period. The vast financial outgoings and the existence of improved economies like Kuwait, Saudi Arabia, and Qatar. In Africa, the majority of people are infected with malaria. Approximately 90% of the deaths occurred because of malaria in Africa, as per World Health Organization (WHO) 2015. In Africa, the market is flourishing due to different measures centered on disease-stopping attempts in the region. For example, Pfizer combined with the UAE government in June to escalate awareness regarding infectious diseases, propelling the market's growth rate in this region.

KEY MARKET PLAYERS:

Some of the promising companies leading the global infectious disease therapeutics market profiled in the report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals and Mitsubishi Tanabe Pharma.

RECENT MARKET DEVELOPMENTS:

• In March 2021, Roche Diagnostics launched the Cobas SARS-CoV-2 Variant Set 1 assay to better understand the emerging coronavirus mutations.
• In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to extend the benefits of point-of-care molecular diagnostics.
• In March 2020, Abbott Labs created ID NOW COVID-19 test kits.
• In January 2018, the University of Glasgow received funding of $ 1.8 million for a project which is part of the Global Challenges Research Fund. This project will develop new tests for parasitic diseases and rapid tests in remote locations to rapidly diagnose and treat infectious diseases.
• In November 2016, QuantuMDx Group received funding from the Bill & Melinda Gates Foundation to develop and test the company's CAPTURE-XT pathogen targeting technology and the Q-POC molecular diagnostic platform for rapid detection and inexpensive tuberculosis. 
• In 2014, Becton, Dickinson, and Company offered the BD FACSPresto point-of-care system for HIV / AIDS. Provides percentage results for CD4 T lymphocytes and hemoglobin concentration. Additionally, in January 2017, the Infectious Disease Research Institute (IDRI) developed a fusion antigen used in a diagnostic test manufactured by InBios International, Inc. for Chagas disease.